Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) gapped down before the market opened on Monday. The stock had previously closed at $71.80, but opened at $67.85. Novozymes A/S shares last traded at $67.8480, with a volume of 906 shares traded.
Novozymes A/S Stock Down 0.9%
The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 0.25. The company has a 50 day simple moving average of $67.50 and a two-hundred day simple moving average of $62.66. The company has a market capitalization of $28.29 billion, a P/E ratio of 40.38, a PEG ratio of 3.09 and a beta of 0.86.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last announced its earnings results on Thursday, November 5th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.26). The company had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Novozymes A/S had a return on equity of 6.56% and a net margin of 15.59%. As a group, equities analysts predict that Novozymes A/S will post 2.45 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in Novozymes A/S stock. Elefante Mark B raised its position in shares of Novozymes A/S (OTCMKTS:NVZMY – Free Report) by 73.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,900 shares of the biotechnology company’s stock after acquiring an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 0.03% of the company’s stock.
About Novozymes A/S
Novozymes A/S was a Denmark-based biotechnology company that developed and produced enzymes and microorganisms for industrial and consumer applications. Its solutions were used in areas including household care, food and beverages, agriculture, animal health and bioenergy.
The company’s products included enzymes used in detergents, baking, brewing and biofuel production, as well as microbial solutions for agricultural and other industrial processes. Novozymes served customers in markets around the world.
In January 2024, Novozymes merged with Danish bioscience company Chr.
Recommended Stories
- Five stocks we like better than Novozymes A/S
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.
